Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45% | Business Wire
Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45% | Business Wire: New study of 6,000+ Medicare patients with advanced prostate cancer shows adding PROVENGE (sipuleucel-T) to treatment reduced risk of death by 45%.
Comments
Post a Comment